Medication development in opioid addiction: Meaningful clinical end points

Nora D. Volkow(National Institute on Alcohol Abuse and Alcoholism), Eric Wargo(National Institutes of Health), Phil Skolnick(Indivior (United States)), Wilson M. Compton(National Institutes of Health), Sharon Hertz(United States Food and Drug Administration), Janet Woodcock(Center for Drug Evaluation and Research), Douglas C. Throckmorton(United States Food and Drug Administration)
Science Translational Medicine
March 28, 2018
10.1126/scitranslmed.aan2595
Cited by 53

Related Papers

Neurocircuitry of Addiction
|Neuropsychopharmacology|2009|5.2k
International Union of Pharmacology. XV. Subtypes of gamma-aminobutyric acidA receptors: classification on the basis of subunit structure and receptor function.
|PubMed|1998|1.2k
Relationship between Nonmedical Prescription-Opioid Use and Heroin Use
|New England Journal of Medicine|2016|1.1k
Addiction: Beyond dopamine reward circuitry
|Proceedings of the National Academy of Sciences|2011|935
Effects of Cannabis Use on Human Behavior, Including Cognition, Motivation, and Psychosis: A Review
|JAMA Psychiatry|2016|856